News List
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
2019-12-21
Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22
Roche T + A immunotherapy research achieves historic breakthrough
2019-12-12
November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical
Hansoh pharm's first sorts of new medicine "Flumatinib" will be approved for listing
2019-11-20
Flumatinib is a tyrosine kinase inhibitor and it’s a second-generation TK inhibitor drug against Bcr
FDA approves Lilly Reyvow
2019-10-21
Recently, Lilly announced that the US FDA approved the company's development of Reyvow (lasmidit
The third anti-tb drug was approved by the FDA
2019-09-24
On August 14th, the FDA approved TB Alliance new fluorine-containing anti-tuberculosis drug Pretoman
Holiday Notice of Mid-Autumn Festival
2019-09-11
To all departments and all employees:According to the related provisions on national holidays &
CPhI North America 2020 in Philadelphia USA Booth#1506
2019-08-26
FluoroPharm will exhibit CPhI North America 2020 in Pennsylvania Convention Center,Philadelphia, PA,
FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
2019-08-19
The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib),
The 150 millionth chemical substance was born!
2019-08-07
According to the American Chemical and Engineering News (C&EN), the American Chemical Abstracts
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
2019-07-12
Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib)